The FDA has approved the sodium/glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin (co-developed by Merck and Pfizer) for glycemic control in adults with type 2 diabetes. Ertugliflozin is approved as monotherapy (Steglatro, 5-mg and 15-mg tablets) to be taken once daily. It is also approved as part of two fixed-dose combinations: with the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin (Steglujan; available as 5-mg ertugliflozin/100-mg sitagliptin and 15-mg/100-mg) to be taken once daily and with metformin (Segluromet; 2.5-mg ertugliflozin/500-mg metformin; 2.5-mg/1000-mg; 7.5-mg/500-mg; and 7.5-mg/1000-mg) to be taken twice daily.